LDL lowering in peripheral arterial disease:are there benefits beyond reducing cardiovascular morbidity and mortality?

References

• Weitz JI, Byrne J, Clagett GP et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 94, 3026-3049 (1996).
   Google Scholar
• Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey. Circulation 110, 738-743 (2004).
   Google Scholar
• Diehm C, Allenberg JR, Pittrow D et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral arterial disease. Circulation 120, 2053-2061 (2009).
   Google Scholar
• McDermott MM, Mehta S, Greenland P. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch. Intern. Med. 159, 387-392 (1999).
   Google Scholar
• McDermott MM, Liu K, Greenland P et al. Functional decline in peripheral arterial disease: associations with ankle brachial index and leg symptoms. JAMA 292, 453-461 (2004).
   Google Scholar
• Dumville JC, Lee AJ, Smith FB, Fowkes FGR. The health related quality of life of people with peripheral arterial disease in the community: the Edinburgh Artery Study. Br. J. Gen. Pract. 54(508), 639-642 (2004).
   Google Scholar
• Catalano M. Epidemiology of critical limb ischemia: northern Italian data. Eur. J. Med. 2, 11-14 (1993).
   Google Scholar
• American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 26, 3333-3341 (2003).
   Google Scholar
• Muluk SC, Muluk VS, Kelley ME et al. Outcome events in patients with claudication: a 15 year study in 2777 patients. J. Vasc. Surg. 33(2), 251-258 (2001).
   Google Scholar
• Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J. Vasc. Surg. 45, 645-654 (2007).
   Google Scholar
• Aung PP, Maxwell H, Jepson RG, Price J, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst. Rev. 4, CD000123 (2007).
   Google Scholar
• Feringa HH, Karagiannis SE, van Waning VH et al. The effect of lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J. Vasc. Surg. 45, 936-943 (2007).
   Google Scholar
• Sastry P, Kaski JC. Atherosclerotic plaque regression - the role of statin therapy. Drugs Today (Barc.) 46(8), 601-608 (2010).
   Google Scholar
• Youssef F, Seifalian AM, Jagroop IA et al. The early effect of lipid lowering treatment on carotid and femoral intima media thickness (IMT). Eur. J. Vasc. Endovasc. Surg. 23(4), 358-364 (2002).
   Google Scholar
• West AM, Anderson JD, Meyer CH et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis 218, 156-162 (2012).
   Google Scholar
• Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431-1443 (2008).
   Google Scholar
• Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361, 2113-2122 (2009).
   Google Scholar
• Pedersen T, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
   Google Scholar
• Pedersen TR, Kjekshus J, Pyorala K et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study. Am. J. Cardiol. 81(3), 333-335 (1998).
   Google Scholar
• Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at 6 months and one year after treatment. Am. J. Cardiol. 92(6), 711-712 (2003).
   Google Scholar
• Mondillo S, Ballo P, Barbati R et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am. J. Med. 114(5), 359-364 (2003).
   Google Scholar
• Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108, 1481-1486 (2003).
   Google Scholar
• McDermott MM, Guralnik JM, Greenland P et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 107, 757-761 (2003).
   Google Scholar
• Giri J, McDermott MM, Greenland P et al. Statin use and functional decline in patients with and without peripheral arterial disease. J. Am. Coll. Cardiol. 47, 998-1004 (2006).
   Google Scholar
• West AM, Anderson JD, Epstein FH et al. Low-density lipoprotein lowering does not improve calf muscle perfusion, energetic or exercise performance in peripheral arterial disease. J. Am. Coll. Cardiol. 58, 1068-1076 (2012).
   Google Scholar
• Hiatt WR, Hirsch AT, Creager MA et al. Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral arterial disease. J. Vasc. Med. 15, 171-179 (2010).
   Google Scholar
• Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease. J. Vasc. Surg. 45(1 Suppl.), S5-S67 (2007).
   Google Scholar
• Rooke TW, Hirsch AT, Misra S et al.
   Google Scholar
• ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Arterial Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124, 2020-2045 (2012).
   Google Scholar
• Tendera M, Aboyans V, Bartelink ML et al. ESC guidelines on the diagnosis and treatment of peripheral arterial diseases: document covering atherosclerotic disease of the extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology. Eur. Heart J. 32(22), 2723-2724 (2012).
   Google Scholar
• Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21, 1712-1719 (2001).
   Google Scholar
• Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler. Thromb. Vasc. Biol. 23, 729-736 (2003).
   Google Scholar
• Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication. Lancet 326, 467-471 (1995).
   Google Scholar
• Laufs U, La F, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97, 1129-1135 (1998).
   Google Scholar
• Creager MA, Cooke JP, Mendelsohn ME et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J. Clin. Invest. 86, 228-234 (1990).
   Google Scholar
• Kinlay S, Plutzky J. Effect of lipid-lowering therapy on vasomotor and endothelial function. Curr. Cardiol. Rep. 1(3), 238-243 (1999).
   Google Scholar
• Brevetti G, Silvestro A, Schiano V et al. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle brachial pressure index. Circulation 108, 2093-2098 (2003).
   Google Scholar
• Maldonado FJ, Miralles Jde H, Aguilar EM, Gonzalez AF, García JR, García FA. Relationship between noninvasively measured endothelial function and peripheral arterial disease. Angiology 60, 725-731 (2009).
   Google Scholar
• Payvandi L, Dyer A, McPherson D et al. Physical activity during daily life and brachial artery flow-mediated dilation in peripheral arterial disease. Vasc. Med. 14, 193-201 (2009).
   Google Scholar
• Balk EM, Karas RH, Jordan HS, Kupelnick B, Chew P, Lau J. Effects of statins on vascular structure and function: a systematic review. Am. J. Med. 117, 775-790 (2004).
   Google Scholar
• Coutinho T, Rooke TW, Kullo IJ. Arterial dysfunction and functional performance in patients with peripheral arterial disease: a review. Vasc. Med. 16, 203-211 (2012). n Excellent overview of the current means of assessing arterial dysfunction in PAD and a review of therapies aimed at improving arterial function and exercise performance.
   Google Scholar
• Vainas T, Stassen FR, de Graaf R et al. C-reactive protein in peripheral arterial disease: relation to the severity of disease and to future cardiovascular events. J. Vasc. Surg. 42(2), 243-251 (2005).
   Google Scholar
• Schillinger M, Exner M, Mlekusch W et al. Statin therapy improves cardiovascular outcome of patients with peripheral arterial disease. Eur. Heart J. 25, 742-748 (2004).
   Google Scholar
• Vasa M, Fichtlscherer S, Adler K et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103, 2885-2890 (2001).
   Google Scholar
• Van Belle E, Rivard A, Chen D et al. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 96, 2667-2674 (1997).
   Google Scholar
• Rosenson RS, Tagney CC. Antiatherothrombotic properties of statins. JAMA 279, 1643-1650 (1998).
   Google Scholar
• Pipinos II, Judge AR, Selsby JT et al. The myopathy of peripheral arterial occlusive disease: Part 1. Functional and histomorphologic changes and evidence for mitochrondrial dysfunction. Vasc. Endovasc. Surg. 42(6), 481-489 (2008).
   Google Scholar
• Pipinos II, Judge AR, Zhu Z et al. Basic science review: the myopathy of peripheral arterial occlusive disease: Part 2. Oxidative stress, neuropathy and shift in muscle fiber type. Vasc. Endovasc. Surg. 42, 101-112 (2008).
   Google Scholar
• Lindner JR, Womack L, Barrett EJ et al. Limb stress-rest perfusion imaging with contrast ultrasound for the assessment of peripheral arterial disease severity. JACC Cardiovasc. Imag. 1(3), 343-350 (2008).
   Google Scholar
• Isbell DC, Epstein FH, Zhong Z et al. Calf muscle perfusion at peak exercise in peripheral arterial disease: measurement by first-pass contrast-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 25(5), 1013-1020 (2007).
   Google Scholar
• Anderson JD, Epstein FH, Meyer CH et al. Multifactorial determinants of functional capacity in peripheral arterial disease: uncoupling of calf muscle perfusion and metabolism. J. Am. Coll. Cardiol. 54, 628-635 (2009).
   Google Scholar
• Rizzo M, Pernice V, Frasheri A, Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. Atherosclerosis 197, 237-241 (2008).
   Google Scholar
• Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomized controlled trial. BMJ 325, 1139 (2002).
   Google Scholar
• Blankenhorn DH, Azen SP, Crawford DW et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 83, 438-447 (1991).
   Google Scholar
• Buchwald H, Bourgades HR, Campos CT et al. Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH). Surgery 120, 672-679 (1996).
   Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (Arbiter ) 2: a double blind, placebocontrolled study of extended-release niacin and atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110, 3512-3517 (2004).
   Google Scholar
• Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein[a]- associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 27, 2094-2099 (2007).
   Google Scholar
• Volpato S, Vigna GB, McDermott MM et al. Lipoprotein (a), inflammation and peripheral arterial disease in a community based sample of older men and women (the InCHIANTI study). Am. J. Cardiol. 105(12), 1825-1830 (2010).
   Google Scholar
• Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J. Am. Coll. Cardiol. 47(5), 921-929 (2006).
   Google Scholar